Thursday - April 23, 2026

Category Archives: Services

Asthma Clinical Trial Pipeline Shows Potential with Active Contributions from 80+ Key Companies | DelveInsight

DelveInsight’s “Asthma Pipeline Insight 2026” report provides comprehensive insights about 80+ companies and 90+ pipeline drugs in the Asthma pipeline landscape. It covers the Asthma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Asthma therapeutics … Continue reading →

Graft Versus Host Disease Clinical Trial Pipeline Accelerates as 45+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight’s, “Graft versus host disease Pipeline Insight 2026” report provides comprehensive insights about 45+ Graft Versus Host Disease Companies and 50+ pipeline drugs in Graft versus host disease pipeline landscape. It covers the Graft Versus Host Disease pipeline drug profiles, … Continue reading →

Chemotherapy Induced Peripheral Neuropathy Clinical Trial Pipeline Gains Momentum: 4+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight’s “Chemotherapy Induced Peripheral Neuropathy Pipeline Insight 2026” report provides comprehensive insights about 4+ companies and 5+ pipeline drugs in the Chemotherapy Induced Peripheral Neuropathy pipeline landscape. It covers the Chemotherapy Induced Peripheral Neuropathy pipeline drug profiles, including clinical and … Continue reading →

Malignant Ascites Clinical Trial Pipeline Appears Robust With 5+ Key Pharma Companies Actively Working in the Domain | DelveInsight

DelveInsight’s “Malignant Ascites Pipeline Insights 2026” Report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Malignant Ascites pipeline landscape. It covers the Malignant Ascites pipeline drug profiles, including clinical and nonclinical stage products. It also covers the … Continue reading →

Age-related Macular Degeneration Treatment Pipeline Shows Strong Momentum as 70+ Pharma Companies in the Race | DelveInsight

DelveInsight’s, “Age-Related Macular Degeneration Pipeline Insight 2026” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Age-Related Macular Degeneration pipeline landscape. It covers the Age-Related Macular Degeneration pipeline drug profiles, including clinical and nonclinical stage products. It … Continue reading →

Acute Heart Failure Clinical Trial Pipeline Expands as 10+ Companies Driving Innovation in the Therapeutics | DelveInsight

DelveInsight’s “Acute Heart Failure Pipeline Insight 2026” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Acute Heart Failure pipeline landscape. It covers the Acute Heart Failure pipeline drug profiles, including clinical and nonclinical stage products. … Continue reading →

Nephrotic Syndrome Clinical Trial Pipeline Shows Potential with Active Contributions from 3+ Key Companies | DelveInsight

DelveInsight’s “Nephrotic Syndrome Pipeline Insight 2026” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in the Nephrotic Syndrome pipeline landscape. It covers the Nephrotic Syndrome pipeline drug profiles, including clinical and nonclinical stage products. It also covers … Continue reading →

CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Clinical Trial Pipeline Accelerates as 5+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight’s “CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Pipeline Insights 2026” report provides comprehensive insights about 5+ CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Companies and 5+ pipeline drugs in the CAR T-Cell Therapy for Acute Lymphoblastic Leukemia pipeline landscape. … Continue reading →

Persistent Epithelial Defect Clinical Trial Pipeline Gains Momentum: 5+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight’s “Persistent Epithelial Defect Pipeline Insights 2026” report provides comprehensive insights about 5+ Persistent Epithelial Defect Companies and 5+ pipeline drugs in the Persistent Epithelial Defect pipeline landscape. It covers the Persistent Epithelial Defect pipeline drug profiles, including clinical and … Continue reading →

BPL-003 Sales Forecast to 2034 Signals Transformational Growth in Treatment-Resistant Depression Market Driven by Rapid-Acting Psychedelic Innovation | DelveInsight

BPL-003 Sales Forecast The global neuropsychiatry landscape is undergoing a paradigm shift, and at the center of this transformation is BPL-003, a next-generation intranasal psychedelic therapy poised to redefine the treatment approach for treatment-resistant depression (TRD) and other neuropsychiatric disorders. … Continue reading →